Pharmaceutical

Gilead’s Vemlidy expands label to treat paediatric chronic HBV

Vemlidy was first approved to treat adults with HBV in 2016. Its label was expanded in 2022 for use in patients 12 years and older.

Mar 30, 2024 - 00:00
Gilead’s Vemlidy expands label to treat paediatric chronic HBV
Vemlidy was first approved to treat adults with HBV in 2016. Its label was expanded in 2022 for use in patients 12 years and older.
Read the original article

Tags:

Previous Article

A biased edge enhancement method for truss-based community search

Next Article

Arvinas gets grant for treatment of prostate cancer with specific compounds

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Otsuka and Astex’s oral Inaqovi wins European approval for AML

Otsuka and Astex’s oral Inaqovi wins European approval ...

Sep 19, 2023

STAT+: KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study

STAT+: KalVista pill reduces swelling symptoms caused b...

Feb 13, 2024

STAT+: AdventHealth sues MultiPlan, alleging a ‘cartel’ that underpays out-of-network medical claims

STAT+: AdventHealth sues MultiPlan, alleging a ‘cartel’...

Aug 11, 2023